trastuzumab + LCN2 siRNA

This combination drug consists of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor type 2 (HER2), and a small interfering RNA (siRNA) designed to knock down Lipocalin-2 (LCN2) expression. Trastuzumab inhibits HER2 receptor signaling, leading to decreased proliferation in HER2-overexpressing tumors, particularly in breast cancer. LCN2 siRNA targets and reduces LCN2 gene expression using RNA interference, which has been shown to decrease cell proliferation and invasion in experimental models. The combination aims to address drug resistance in HER2-positive cancers, especially breast cancer, by simultaneously blocking HER2 signaling and LCN2-mediated pathways, potentially enhancing antitumor efficacy in cases where resistance to trastuzumab develops[1][6].